Abstract 3411
Background
Gastrointestinal stromal tumours (GISTs) account for 1% of all primary gastrointestinal cancers. In cancer, suppressive immune checkpoints, including butyrophilin sub-family 3A/CD277 receptors (BTN3A), programmed death protein (PD-1) and its ligand PD-L1, are often hyper-activated to ensure an effective evasion of tumor cells from immune surveillance. Since recent studies showed that PD-1 and PD-L1 expression in cancer may be an important prognostic factor, the aim of our study was to investigate if soluble forms of inhibitory immune checkpoints can help predict survival in metastatic GIST patients.
Methods
Using specific homemade ELISA assays not yet commercially available, the plasma PD-1, PD-L1, BTN3A1 and pan-BTN3As levels were analyzed in 20 metastatic GIST patients harbouring c-KIT exon 11 mutations, before starting treatment with 400 mg Imatinib. Survival curves were estimated by using the Kaplan-Meier method and log-rank test to evaluate significant differences among them. Data was generated using the MedCalc software for Windows, version 18.2.1.
Results
Kaplan-Meier survival analysis was used to characterize prognostic relevance of soluble PD-1, PD-L1, BTN3A1 and pan-BTN3As in metastatic GIST patients, suggesting that their plasma levels could serve as survival predictor. For each analyzed biomarker, statistically significant differences in progression free-survival (PFS) between patients with plasma concentrations above and under median values were detected. Plasma level thresholds correlated with shorter survival and poor prognosis were established for PD-1 (>6.89 ng/ml), PD-L1 (>0.74 ng/ml), BTN3A1 (>7.19 ng/ml) and pan-BTN3As (>4.38 ng/ml). Conversely, patients with plasma levels under thresholds showed a median PFS that was approximately 58 months longer than to the previous.
Conclusions
Our study, for the first time, reveals that monitoring the concentration of soluble forms of inhibitory immune checkpoints in plasma can help predict survival in metastatic GIST patients and therefore improve their treatments. We showed that high plasma levels of these immune checkpoints correlate with poor outcome and could be used in future as prognostic factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Presenter: Francesca Zannier
Session: Poster Display session 1
Resources:
Abstract
2433 - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
Presenter: Cheol-Hee Shin
Session: Poster Display session 1
Resources:
Abstract
2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation
Presenter: Antonin Levy
Session: Poster Display session 1
Resources:
Abstract
3213 - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor
Presenter: Alexey Bogdanov
Session: Poster Display session 1
Resources:
Abstract
3722 - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.
Presenter: Sungwon Shin
Session: Poster Display session 1
Resources:
Abstract
5805 - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging Guided Cancer Photothermal Therapy
Presenter: sheng wang
Session: Poster Display session 1
Resources:
Abstract
5251 - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Presenter: Ivan Zaporozhchenko
Session: Poster Display session 1
Resources:
Abstract
3657 - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes
Presenter: Bianca Cabral
Session: Poster Display session 1
Resources:
Abstract
2839 - Obesity and prognosis in breast cancer
Presenter: Noha Ibrahim
Session: Poster Display session 1
Resources:
Abstract
5132 - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells
Presenter: Chang Liu
Session: Poster Display session 1
Resources:
Abstract